4.4 Article

PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung

期刊

HUMAN PATHOLOGY
卷 58, 期 -, 页码 7-14

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2016.07.007

关键词

Programmed cell death 1; Programmed cell death 1 ligand 1; Epithelial-mesenchymal transition; Adenocarcinorna of the lung; Immune checkpoint; Cancer immunotherapy

资金

  1. grant of the Korea Health Technology R&D Project through Korea Health Industry Development Institute
  2. Ministry of Health and Welfare, Republic of Korea [HI14C1277]

向作者/读者索取更多资源

PD-1/PD-Ll targeted immunotherapy has emerged as a promising therapeutic strategy for pulmonary adenocarcinoma (pADC). Epithelial-to-mesenchymal transition (EMT) is involved in the progression and immune evasion of cancers. Therefore, we investigated the association between PD-L1 expression and EMT phenotype in pADC. Immunohistochemistry for E-cadherin (epithelial marker), ZEB1, SNAIL, SLUG, vimentin (mesenchymal markers), PD-L1, CD8, and PD-1 was performed on 477 cases of pADC. Cases were classified into epithelial, mesenchymal, epithelial-mesenchymal, and unspecified types based on immunohistochemical results. PD-L1 expression was scored as 0 in 14.0% (n = 67), 1 in 26.4% (n = 126), 2 in 51.2% (n = 244), and 3 in 8.4% (n = 40). PD-Ll score was positively correlated with SNAIL and vimentin H scores (P <.001, both). After dichotomising patients into PD-L1-negative and PD-Ll positive groups, PD-L1 positivity was significantly higher in patients with mesenchymal (71.2%; 84/118) and epithelial-mesenchymal (62.7%; 84/134) phenotypes compared with those with epithelial (50.6%; 44/87) and unspecified (50.0%; 35/70) phenotypes (P = .005). The significant association between PD-L1 expression and EMT phenotype was maintained in EGFR-mutated pADCs. Moreover, cases with EMT phenotype (ie, mesenchymal and epithelial-mesenchymal) were infiltrated by higher numbers of CD8(+) and PD-1(+) cells than those with epithelial and unspecified phenotypes in EGFR-mutated pADCs (P = .043 for CD8(+) cells and P <.001 for PD-1(+) cells). Particularly, cases with EMT phenotype and PD-L1 expression showed the greatest amount of CD8(+) and PD-1(+) cells in EGFR-mutated cases (P = .043 for CD8(+) cells and P = .005 for PD-1(+) cells). This study demonstrates that EMT phenotype is related to PD-L1 overexpression in pADC cells and patients with EMT-phenotype pADC may benefit from PD-1/PD-L1-blocking immunotherapy. (C) 2016 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据